Demant (DEMANT) Stock Overview
Operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
DEMANT Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Demant A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 291.00 |
| 52 Week High | DKK 298.60 |
| 52 Week Low | DKK 175.00 |
| Beta | 0.76 |
| 1 Month Change | 4.53% |
| 3 Month Change | 21.45% |
| 1 Year Change | 13.49% |
| 3 Year Change | 0.034% |
| 5 Year Change | -17.96% |
| Change since IPO | 1,617.63% |
Recent News & Updates
Narrative Update • Aug 04
DEMANT: Future Returns Will Hinge On Executing Margin And Revenue Mix Improvements
The analyst price target for Demant has moved from DKK 251 to DKK 277, as analysts factor in updated assumptions on revenue growth, margins and valuation following a mix of target hikes and rating changes across recent research. Analyst Commentary Recent research on Demant shows a mix of optimism and caution, with higher price targets sitting alongside more neutral ratings.
Narrative Update • Jul 21
DEMANT: Growth Inflection Expectations In European Medtech Set To Drive Upside
The analyst price target for Demant has been raised from DKK 300 to DKK 310. Analysts point to modest adjustments in fair value, discount rate, revenue growth assumptions and future P/E expectations, alongside mixed recent rating changes that reflect both perceived growth potential and valuation constraints.Narrative Update • Jul 07
DEMANT: Hearing Market Turnaround And Sector Inflection Shape Balanced Outlook
Analysts have adjusted the fair value estimate for Demant to DKK 300 from DKK 316, reflecting updated assumptions on revenue growth, profit margins, and future P/E multiples in light of recent price target increases from DKK 226 to DKK 258 at Deutsche Bank and from DKK 210 to DKK 290 at Morgan Stanley. Analyst Commentary Recent research on Demant points to a more constructive tone, with several bullish analysts revisiting their assumptions on the stock and adjusting price targets to reflect updated views on growth potential and valuation.Recent updates
Narrative Update • Aug 04
DEMANT: Future Returns Will Hinge On Executing Margin And Revenue Mix Improvements
The analyst price target for Demant has moved from DKK 251 to DKK 277, as analysts factor in updated assumptions on revenue growth, margins and valuation following a mix of target hikes and rating changes across recent research. Analyst Commentary Recent research on Demant shows a mix of optimism and caution, with higher price targets sitting alongside more neutral ratings.Narrative Update • Jul 21
DEMANT: Growth Inflection Expectations In European Medtech Set To Drive Upside
The analyst price target for Demant has been raised from DKK 300 to DKK 310. Analysts point to modest adjustments in fair value, discount rate, revenue growth assumptions and future P/E expectations, alongside mixed recent rating changes that reflect both perceived growth potential and valuation constraints.Narrative Update • Jul 07
DEMANT: Hearing Market Turnaround And Sector Inflection Shape Balanced Outlook
Analysts have adjusted the fair value estimate for Demant to DKK 300 from DKK 316, reflecting updated assumptions on revenue growth, profit margins, and future P/E multiples in light of recent price target increases from DKK 226 to DKK 258 at Deutsche Bank and from DKK 210 to DKK 290 at Morgan Stanley. Analyst Commentary Recent research on Demant points to a more constructive tone, with several bullish analysts revisiting their assumptions on the stock and adjusting price targets to reflect updated views on growth potential and valuation.Narrative Update • Jun 23
DEMANT: Fair Value View Balances Growth Inflection Hopes With Execution Risks
Analysts have lifted their price expectations for Demant, with the consensus fair value estimate moving from DKK 240.32 to DKK 251.11. Recent research points to a higher price target range supported by updated views on growth, profitability and future P/E multiples.Narrative Update • Jun 05
DEMANT: Raised Fair Value And EU AI Rules May Shape Re Rating
Analysts have lifted the fair value estimate for Demant from DKK 229.83 to DKK 240.32. This reflects updated targets from firms such as Deutsche Bank and Morgan Stanley and is supported by assumptions for slightly higher revenue growth, improved profit margins, and a modestly lower discount rate, while keeping future P/E expectations broadly unchanged.Narrative Update • Apr 27
DEMANT: 2026 EBIT Guidance May Support Re Rating Despite Mixed Research
Analysts have adjusted their price target for Demant slightly lower to DKK 229.83 from DKK 232.44. This reflects a mix of recent target increases and cuts across major banks, as well as a modest recalibration of fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Narrative Update • Apr 08
DEMANT: Recent Upgrades And 2026 Guidance May Support Re Rating
The updated analyst price target for Demant now sits at DKK 232, up modestly from DKK 232. The small adjustment reflects a mix of recent upgrades and price target cuts as analysts reassess assumptions for discount rates, revenue growth, profit margins and future P/E levels.Narrative Update • Mar 25
DEMANT: Recent Upgrades And 2026 Guidance May Support Further Upside
Analysts have trimmed the fair value estimate for Demant slightly to DKK 231.61 from DKK 232.17, reflecting a modest recalibration of price targets after a mix of recent upgrades and target reductions across the Street. Analyst Commentary Recent research on Demant has been mixed, with both upgrades and target cuts contributing to the slightly lower blended fair value estimate.Narrative Update • Mar 10
DEMANT: Recent Upgrade And 2026 Guidance May Support Further Upside
Our updated narrative keeps the fair value estimate steady at DKK 232.17 per share, reflecting a balanced view of recent Street research. One analyst raised Demant to a Buy with a DKK 230 target, while several others trimmed their price targets.Narrative Update • Feb 22
DEMANT: Recent Rating Upgrade May Support Future Upside Despite Softer Margins
The updated analyst price target for Demant has moved slightly lower to about DKK 232 from roughly DKK 238, as analysts balance a modestly higher assumed revenue growth rate against slightly softer margin expectations and a higher discount rate, with recent Street research showing a mix of target cuts from several banks and one upgrade to Buy at DKK 230. Analyst Commentary Recent Street research around Demant reflects a split view, with one Upgrade to Buy around DKK 230 contrasting with several lower price targets and at least one downgrade.Narrative Update • Feb 08
DEMANT: Future Margin Resilience And Cautious Ratings May Support Upside Potential
Analysts have trimmed their price targets on Demant by about DKK 28, reflecting updated assumptions for slightly higher revenue growth, a lower future P/E multiple, and a modestly softer profit margin, in line with recent cautious moves from several major banks and a Sector Perform stance from RBC Capital. Analyst Commentary Recent research updates on Demant point to a broadly cautious tone, with several banks adjusting price targets and at least one downgrade in rating.Narrative Update • Jan 24
DEMANT: Stable Guidance And Sector Perform Rating Will Support Future Earnings Resilience
Analysts have reduced their price target on Demant by roughly DKK 2 to about DKK 266, reflecting only modest adjustments to growth, margin and P/E assumptions and citing limited scope for the company to increase its organic revenue share over the medium term. Analyst Commentary Recent research paints a fairly balanced picture for Demant, with the current DKK 250 price target and Sector Perform rating pointing to a view that the shares are reasonably valued on existing growth and margin assumptions.Analysis Article • Jan 22
An Intrinsic Calculation For Demant A/S (CPH:DEMANT) Suggests It's 24% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Demant fair value estimate is kr.302 Current share price of...Narrative Update • Jan 07
DEMANT: Future Earnings Resilience Will Rely On Stable Market Position
Analysts have trimmed their price target on Demant slightly from DKK 271.65 to DKK 268. This reflects modestly softer assumptions for revenue growth and future P/E, partly offset by a marginally higher expected profit margin and recent views that organic revenue share gains may be limited for now.Narrative Update • Dec 15
DEMANT: Earnings Resilience Will Rely On Stable Market Position
Analysts have modestly reduced their price target on Demant to approximately DKK 272 from about DKK 275. This reflects slightly softer assumptions for revenue growth and margins and a view that the company has limited opportunity to gain organic revenue share over the medium term.Analysis Article • Dec 15
Is Now The Time To Look At Buying Demant A/S (CPH:DEMANT)?
Demant A/S ( CPH:DEMANT ), might not be a large cap stock, but it saw significant share price movement during recent...Narrative Update • Nov 28
DEMANT: Market Position And Cost Discipline Will Support 2025 Earnings
Analysts have slightly reduced their price target for Demant from DKK 277.69 to DKK 275.18, citing limited expectations for organic revenue growth in the medium term. Analyst Commentary Recent coverage on Demant reflects a measured outlook, with analysts assessing both the company’s growth prospects and challenges in the current landscape.Analysis Article • Nov 27
Pinning Down Demant A/S' (CPH:DEMANT) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 17.5x Demant A/S ( CPH:DEMANT ) may be sending bearish signals at the...Narrative Update • Nov 14
DEMANT: Improved Revenue Outlook Will Drive Earnings Growth Into 2025
Analysts have lowered their price target for Demant from DKK 284.19 to DKK 277.69. This change is due to a slight increase in the discount rate and marginal declines in profit margin projections, partially offset by improved revenue growth expectations.Narrative Update • Oct 30
DEMANT: Rising Share Buybacks Will Drive Medium-Term Upside Momentum
Analysts have modestly lowered their price target for Demant to DKK 284.19 from DKK 291.50, citing slight adjustments in the company’s discount rate, future profit margin, and anticipated revenue growth. Analyst Commentary Recent updates from major financial institutions have shed light on the divergent perspectives regarding Demant’s outlook and valuation potential.Analysis Article • Oct 08
Is Demant A/S (CPH:DEMANT) Trading At A 47% Discount?
Key Insights The projected fair value for Demant is kr.437 based on 2 Stage Free Cash Flow to Equity Demant's kr.230...Analysis Article • Sep 16
Is There Now An Opportunity In Demant A/S (CPH:DEMANT)?
Demant A/S ( CPH:DEMANT ), is not the largest company out there, but it saw significant share price movement during...Narrative Update • Sep 05
Aging Demographics And Hearing Care Awareness Will Shape Future Progress
Analysts have maintained an upbeat outlook on Demant due to increased confidence in its guidance, improved fundamentals, and decreased downside risks, resulting in the consensus price target holding steady at DKK291.50. Analyst Commentary Improved confidence in Demant's ability to achieve its guidance, considered more achievable compared to peers.Analysis Article • Sep 02
Demant (CPH:DEMANT) Is Doing The Right Things To Multiply Its Share Price
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
New Narrative • Feb 09
Expanding Into Denmark, Germany, And Italy Will Strengthen Future Position In Hearing Care Market
Strategic divestments and focus on hearing healthcare aim to reduce complexity, improve margins, and streamline operations.Shareholder Returns
| DEMANT | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | 0.5% | 0.9% | 1.2% |
| 1Y | 13.5% | -15.5% | -0.8% |
Return vs Industry: DEMANT exceeded the Danish Medical Equipment industry which returned -15.5% over the past year.
Return vs Market: DEMANT exceeded the Danish Market which returned -0.8% over the past year.
Price Volatility
| DEMANT volatility | |
|---|---|
| DEMANT Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.1% |
| 10% least volatile stocks in DK Market | 2.4% |
Stable Share Price: DEMANT has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: DEMANT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1904 | 26,616 | Søren Nielsen | www.demant.com |
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019.
Demant A/S Fundamentals Summary
| DEMANT fundamental statistics | |
|---|---|
| Market cap | DKK 62.26b |
| Earnings (TTM) | DKK 2.42b |
| Revenue (TTM) | DKK 24.63b |
25.3x
P/E Ratio2.5x
P/S RatioIs DEMANT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEMANT income statement (TTM) | |
|---|---|
| Revenue | DKK 24.63b |
| Cost of Revenue | DKK 5.85b |
| Gross Profit | DKK 18.78b |
| Other Expenses | DKK 16.36b |
| Earnings | DKK 2.42b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.49 |
| Gross Margin | 76.25% |
| Net Profit Margin | 9.84% |
| Debt/Equity Ratio | 149.4% |
How did DEMANT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 17:23 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Demant A/S is covered by 38 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Edward Ridley-Day | Barclays |
| Hassan Al-Wakeel | Barclays |